{"nctId":"NCT02566993","briefTitle":"Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer","startDateStruct":{"date":"2016-08-30","type":"ACTUAL"},"conditions":["Small-cell Lung Cancer"],"count":613,"armGroups":[{"label":"Experimental Arm","type":"EXPERIMENTAL","interventionNames":["Drug: Lurbinectedin (PM01183)","Drug: Doxorubicin (DOX)"]},{"label":"Control Arm 1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Doxorubicin (DOX)","Drug: Cyclophosphamide (CTX)","Drug: Vincristine (VCR)"]},{"label":"Control Arm 2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Topotecan"]}],"interventions":[{"name":"Lurbinectedin (PM01183)","otherNames":[]},{"name":"Doxorubicin (DOX)","otherNames":[]},{"name":"Cyclophosphamide (CTX)","otherNames":[]},{"name":"Vincristine (VCR)","otherNames":[]},{"name":"Topotecan","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Voluntary written informed consent\n2. Adult patients ≥ 18 years\n3. Histologically or cytologically confirmed diagnosis of limited or extensive stage SCLC which failed one prior platinum-containing regimen and with a chemotherapy-free interval (CTFI, time from the last dose of first-line chemotherapy to the occurrence of progressive disease) ≥ 30 days. Small-cell carcinoma of unknown primary site with or without neuroendocrine features confirmed in histology test(s) performed on metastatic lesion(s) are eligible, if Ki-67/MIB-1 is expressed in \\>50% of tumor cells.\n4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2.\n5. Adequate hematological, renal, metabolic and hepatic function within 7-10 days prior to randomization\n6. At least three weeks since last prior anticancer treatment and adequate recovery from prior treatment toxicity\n7. Prior radiotherapy (RT): At least four weeks since completion of whole-brain irradiation, at least two weeks since completion of prophylactic cranial irradiation, and to any other site.\n8. Evidence of non-childbearing status for women of childbearing potential (WOCBP). WOCBP must agree to use a highly effective contraceptive measure up to six weeks after treatment discontinuation. Fertile male patients with WOCBP partners should use condoms during treatment and for four months following the last investigational medicinal product dose.\n\nExclusion Criteria:\n\n1. More than one prior chemotherapy-containing line(re-challenge with the same initial regimen is not allowed)\n2. Patients who never received platinum-containing regimen for Small-cell Lung Cancer (SCLC)\n3. Prior treatment with PM01183, topotecan or anthracyclines.\n4. Limited-stage patients who are candidates for local or regional therapy\n5. Impending need for palliative RT or surgery for pathological fractures and/or for medullary compression within four weeks prior to randomization.\n6. Symptomatic or progressing or steroid requiring Central Nervous System (CNS) involvement disease at least four weeks prior to randomization\n7. Concomitant diseases/conditions:\n\n   Angina, myocardial infarction, congestive heart failure or clinically significant valvular heart disease, arrhythmia, immunodeficiency (including known HIV seropositive), ongoing or treatment-requiring chronic liver disease, active infection, oxygen requirement within two weeks prior to randomization, diffuse interstitial lung disease (ILD) or pulmonary fibrosis, second invasive malignancy treated with chemotherapy and/or radiotherapy, invasive fungal infections requiring systemic treatment within 12 weeks of randomization.\n8. Pregnant or breast feeding women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS)","description":"Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"7.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference in Overall Survival Between Lurbinectedin/Doxorubicin (DOX) and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 12 Months","description":"Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6","spread":null},{"groupId":"OG001","value":"24.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 18 Months","description":"Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.9","spread":null},{"groupId":"OG001","value":"15.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 24 Months","description":"Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"8.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS) by Independent Review Committee","description":"Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival Rate at 6 Months by Independent Review Committee","description":"Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"24.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival Rate at 12 Months by Independent Review Committee","description":"Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Antitumor Response by Independent Review Committee","description":"Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.\n\nCR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"87","spread":null}]},{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"116","spread":null}]},{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"52","spread":null}]},{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate by Independent Review Committee","description":"Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.\n\nCR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","spread":null},{"groupId":"OG001","value":"29.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response by Independent Review Committee","description":"Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.\n\nCR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"3.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival in Patients With Chemotherapy-free Interval ≥ 90 Days","description":"Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":null},{"groupId":"OG001","value":"8.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival in Patients With Chemotherapy-free Interval ≥90 Days","description":"Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Antitumor Response in Patients With Chemotherapy-free Interval ≥ 90 Days","description":"Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.\n\nCR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"68","spread":null}]},{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"73","spread":null}]},{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"35","spread":null}]},{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate in Patients With Chemotherapy-free Interval ≥ 90 Days","description":"Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.\n\nCR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.0","spread":null},{"groupId":"OG001","value":"35.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response in Patients With Chemotherapy-free Interval ≥ 90 Days","description":"Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.\n\nCR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival in Patients With Chemotherapy-free Interval < 90 Days","description":"Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival in Patients With Chemotherapy-free Interval <90 Days","description":"Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Antitumor Response in Patients With Chemotherapy-free Interval <90 Days","description":"Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.\n\nCR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"19","spread":null}]},{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"43","spread":null}]},{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"17","spread":null}]},{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate in Patients With Chemotherapy-free Interval <90 Days","description":"Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.\n\nCR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","spread":null},{"groupId":"OG001","value":"18.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response in Patients With Chemotherapy-free Interval <90 Days","description":"Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.\n\nCR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival in Patients Without Central Nervous System Involvement at Baseline","description":"Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival in Patients Without Central Nervous System Involvement at Baseline","description":"Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Antitumor Response in Patients Without Central Nervous System Involvement at Baseline","description":"Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.\n\nCR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"76","spread":null}]},{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"100","spread":null}]},{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"40","spread":null}]},{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate in Patients Without Central Nervous System Involvement at Baseline","description":"Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.\n\nCR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.0","spread":null},{"groupId":"OG001","value":"30.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response in Patients Without Central Nervous System Involvement at Baseline","description":"Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.\n\nCR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival in Patients With Central Nervous System Involvement at Baseline","description":"Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":null},{"groupId":"OG001","value":"6.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival in Patients With Central Nervous System Involvement at Baseline","description":"Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Antitumor Response in Patients With Central Nervous System Involvement at Baseline","description":"Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.\n\nCR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"16","spread":null}]},{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate in Patients With Central Nervous System Involvement at Baseline","description":"Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.\n\nCR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":null},{"groupId":"OG001","value":"24.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response in Patients With Central Nervous System Involvement at Baseline","description":"Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1.\n\nCR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":126,"n":303},"commonTop":["Fatigue","Anaemia","Neutropenia","Nausea","Thrombocytopenia"]}}}